[Pneumococcal conjugate vaccine in children].
Streptococcus pneumoniae is one of the major causes of severe invasive infections in young children. As purified polysaccharide are not immunogenic in infants, vaccines containing the bacterial polysaccharide conjugated to a carrier protein have been developed according to the model that has proved to be effective for Haemophilus influenzae b and group C meningococcus. A conjugate vaccine containing the 7 serotypes responsible for about 90% of the invasive infections occuring in children in the United States has been shown to have a 97% protective efficacy against infections caused by vaccine serotypes. Pneumococcal conjugate vaccines are also protective, although to a lesser extent, against otitis media caused by vaccine serotypes, but the global impact of these vaccines on the total number of otitis media remains limited. The large scale use of this vaccine has demonstrated its epidemiological impact on the burden of invasive pneumococcal disease in the age group targeted by vaccination as well as among the adult contacts of the vaccines. On the basis of these informations, the conjugate pneumococcal vaccine has been included in the recommended vaccination schedule in Belgium. However, repeated vaccine shortages as well as the high cost of the product make the implementation of this recommendation uncertain.
Lévy
J
J
Service de Pédiatrie, CHU Saint-Pierre, Bruxelles.
Swennen
B
B
D002675:Child, Preschool; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D007223:Infant; D022401:Meningococcal Vaccines / Q000276:immunology; D011008:Pneumococcal Infections / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000276:immunology
D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D022401:Meningococcal Vaccines; D022242:Pneumococcal Vaccines